Delpor, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2009-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.delpor.com
Safety, Tolerability, and Pharmacokinetics of Naltrexone Implant (DLP-160)
Phase 1
Completed
- Conditions
- Opiod Use Disorder
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Delpor, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05304364
- Locations
- 🇦🇺
CMAX, Adelaide, South Australia, Australia
Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant
Phase 1
Completed
- Conditions
- Schizophrenia
- Interventions
- Combination Product: Risperidone
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Delpor, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT04418466
- Locations
- 🇺🇸
Segal Trials, Miami Lakes, Florida, United States
🇺🇸Collaborative Neuroscience Research, Long Beach, California, United States
© Copyright 2025. All Rights Reserved by MedPath